PDB1

DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGE OF NEUROPATHIC SYMPTOMS
Currie CJ¹, Cawley S², Morgan CL¹, McEwan P¹, Price P¹, Covington M³, Peters JR^4
1Cardiff University, Cardiff, Wales, United Kingdom; ² NHS Wales, Cardiff, United Kingdom; ³ Eli Lilly and Company, Indianapolis, IN, USA; ⁴ University Hospital of Wales, Cardiff, United Kingdom

PDB2

WITHDRAWN

PDB3

WITHDRAWN

PDB4

HEALTH CARE UTILIZATION AND EXPENDITURES ASSOCIATED WITH USE OF INSULIN GLARGINE
Miller DR¹, Gardner J², Hendricks A², Fincke BG^1
1Boston University School of Public Health, Bedford, MA, USA; ² Boston University School of Public Health, Boston, MA, USA

PDB5

IMPROVED TREATMENT SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH EXENATIDE OR INSULIN GLARGINE
Secnik K¹, Hayes C¹, Matza L², Kim S³, Oglesby A⁴, Yurgin N¹, Brodows R¹, Malley K^2
1Eli Lilly and Company, Indianapolis, IN, USA; ² The MEDTAP Institute at UBC, Bethesda, MD, USA; ³ Florida International University, Miami, FL, USA; ⁴ Eli Lilly and Company Limited, Indianapolis, IN, USA

PDB6

REDUCTION IN DIABETES DRUGS USE AND DRUG COSTS IN OBESE PEOPLE TREATED WITH ORLISTAT
Rowe R¹, Cowx M¹, Poole C², McEwan P³, Walker M^4
1Wythenshawe Hospital, Manchester, United Kingdom; ² Cardiff Research Consortium, Cardiff, United Kingdom; ³ Cardiff University, Cardiff, Wales, United Kingdom; ⁴ Roche Products Ltd, Welwyn Garden City, Hertfordshire, United Kingdom

PDB7

THE METABOLIC EFFECTS OF ORLISTAT AND ROSIGLITAZONE ON INSULIN ACTION IN A GROUP OF CHINESE PATIENTS AFFECTED BY THE METABOLIC SYNDROME
Loh SC¹, Tomlinson B², Chan JC², Lee KK^2
1The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong; ² The Chinese University of Hong Kong, Hong Kong, China

PDB8

CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) AND EZETIMIBE IN STATIN-TREATED TYPE 2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS
Liens D¹, Roze S², Valentine WJ², Minshall ME³, Palmer AJ², Renaudin C^1
1Merck Santé, Lyon, France; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ CORE - USA, LLC, Fishers, IN, USA

PDB9

PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) TO STATIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES
Renaudin C¹, Roze S², Palmer AJ², Valentine WJ², Minshall ME³, Liens D^1
1Merck Santé, Lyon, France; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ CORE - USA, LLC, Fishers, IN, USA

PDB10

TYPE 2 DIABETES IN GERMANY: PREVALENCE AND MEDICATION USE
Yurgin N¹, Secnik K¹, Lage MJ^2
1Eli Lilly and Company, Indianapolis, IN, USA; ² HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PDB11

Withdrawn

PDB12

BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ROSIGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES. THE ITALIAN NHS PERSPECTIVE
Novelli M, Avallone A, Frizzo V, Bamfi F
GlaxoSmithKline, Verona, VR, Italy

PDB13

THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS
Kamiñski B¹, Niewada M², Latek M¹, Lis J³, Gierczynski J^3
1Warsaw School of Economics, Warszawa, mazowieckie, Poland; ² Medical University of Warsaw, Warsaw, Poland; ³ Sanofi-aventis Poland, Warsaw, Poland

PDB14

COST OF DIABETES MELLITUS TYPE 2 AND SELF MEASUREMENT OF BLOOD GLUCOSE IN GERMANY: A HEALTH INSURANCE PERSPECTIVE
Weber C¹, Neeser K¹, Wenzel H², Schneider B^3
1Institute for Medical Informatics and Biostatistics (IMIB), Basel, BS, Switzerland; ² University of Bielefeld, Bielefeld, Germany; ³ Institut für Biometrie, Hannover, Germany

PDB15

A MODEL BASED ANALYSIS OF COSTS AND EFFECTIVENESS OF CHIROPODIST CARE IN DIABETEC PATIENTS
Habacher W¹, Rakovac I¹, Plank J², Haas W², Beck P¹, Pieber TR^1
1Joanneum Research, Graz, Styria, Austria; ² Medical University Graz, Graz, Styria, Austria

PDB16

COSTS ASSOCIATED WITH GLUCOSE CONTROL IN THE NON-DIABETIC CRITICALLY ILL PATIENT
Conner TM¹, Bolster SR¹, Rankin S¹, Inman GM¹, Rascati KL^2
1Seton Healthcare Network, Austin, TX, USA; ² University of Texas at Austin, Austin, TX, USA

PDB17

ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES IN GERMANY AND SWEDEN
Berger W¹, Roze S², Palmer AJ², Valentine WJ², Liens D³, Renaudin C^3
1Merck KGgA, Darmstadt, Germany; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ Merck Santé, Lyon, France

PDB18

COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN^®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK PERSPECTIVE
Paschen B¹, Roze S², Palmer AJ², Valentine WJ², Liens D³, Renaudin C^3
1Merck KGaA, Darmstadt, Germany; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ Merck Santé, Lyon, France

PDB19

ECONOMIC EVALUATION OF SWITCHING TYPE 1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE IN A BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING
Palmer AJ¹, Wittrup-Jensen KU², Hansen JB³, Roze S¹, Valentine WJ^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany; ³ Novo Nordisk A/S, Bagsværd, Denmark

PDB20

BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE 2 DIABETES: LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
Palmer AJ¹, Lammert M², Valentine WJ¹, Ray JA¹, Brandt AS³, Roze S^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk, Bagsvaerd, Denmark; ³ Novo Nordisk Scandinavia AB, Malmö, Sweden

PDB21

COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY IN TYPE 1 DIABETES USING INSULIN DETEMIR+INSULIN ASPART OR HUMAN SOLUBLE INSULIN-BASED BASAL/BOLUS REGIMENS IN GERMANY
Valentine WJ¹, Wittrup-Jensen KU², Palmer AJ¹, Roze S^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany

PDB22

ASSESSING THE EFFICIENCY OF USING CONTINUOUS SUBCUTANEOUS INSULIN -INFUSION (CSII) VERSUS MULTIPLE DAILY INJECTIONS (MDI) IN SPANISH DIABETES MELLITUS TYPE 1 (DM1) PATIENTS. COST – EFFECTIVENESS ANALYSIS.
Castell C¹, Palmer AJ², Rodriguez JM³, Roze S², Serrano-Contreras D³, Zakrzewska K^4
1Generalitat de Catalunya, Barcelona, Catalunya, Spain; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ Medtronic Iberica, Madrid, Madrid, Spain; ⁴ Medtronic Europe SA, Tolochenaz, Sarl, Switzerland

PDB23

ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE 1 DIABETES IN GERMANY
Palmer AJ¹, Valentine WJ¹, Wittrup-Jensen KU², Roze S^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany

PDB24

ASSESSMENT OF THE LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART+METFORMIN VERSUS HUMAN INSULIN+METFORMIN REGIMENS IN TYPE 2 DIABETES IN GERMANY BASED ON THE CLINICAL FINDINGS OF THE PHAZIT STUDY
Roze S¹, Wittrup-Jensen KU², Haüser C², Valentine WJ¹, Palmer AJ^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany

PDB25

FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE^®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE 2 DIABETES PATIENTS IN FRANCE
Cugnardey N¹, Roze S², Palmer AJ², Minshall ME³, Valentine WJ², Renaudin C^1
1Merck Santé, Lyon, France; ² CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ³ CORE - USA, LLC, Fishers, IN, USA

PDB26

COMPARATIVE EVALUATION OF THE LONG-TERM COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 AND INSULIN GLARGINE IN A SUB-POPULATION OF POORLY CONTROLLED PATIENTS WITH TYPE 2 DIABETES RECEIVING ORAL ANTIDIABETIC AGENTS
Cobden D¹, Nicklasson L¹, Raskin P², Garber A³, Ray J⁴, Valentine W⁴, Palmer A⁴, Roze S^4
1Novo Nordisk, Princeton, NJ, USA; ² University of Texas Southwestern Medical Center, Dallas, TX, USA; ³ Baylor College of Medicine, Houston, TX, USA; ⁴ CORE - Center for Outcomes Research, Binningen, Basel, Switzerland

PDB27

COST-EFFECTIVENESS OF ACARBOSE IN ADDITION TO EXISTING TREATMENTS IN TYPE 2 DIABETES IN GERMANY
Roze S¹, Valentine WJ¹, Evers T², Palmer AJ^1
1CORE - Center for Outcomes Research, Binningen, Switzerland; ² Bayer Healthcare AG, Wuppertal, Germany

PDB28

COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE 1 DIABETES USING INSULIN DETEMIR+HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM+HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY
Valentine WJ¹, Palmer AJ¹, Wittrup-Jensen KU², Roze S^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany

PDB29

HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES
Thompson M¹, Sauriol L², Grima D^3
1Innovus Research Inc, Burlington, ON, Canada; ² Sanofi-aventis, Laval, QC, Canada; ³ Cornerstone Research Group Inc, Oakville, ON, Canada

PDB30

COST-EFFECTIVENESS OF PREVENTIVE INTERVENTIONS IN DIABETES MELLITUS AND ITS (MACROVASCULAR)COMPLICATIONS: A SYSTEMATIC LITERATURE REVIEW
Vijgen SMC, Hoogendoorn M, Baan C, de Wit A, Limburg W, Feenstra T
National Institute for Public Health and the Environment, Bilthoven, Netherlands

PDB31

A LIFETIME MODELLED ECONOMIC EVALUATION COMPARING PIOGLITAZONE AND ROSIGLITAZONE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE UK
Tilden D¹, Mariz S², Diamantopoulos A¹, O'Bryan-Tear G^2
1M-TAG, A division of IMS Health Economics and Outcomes Research, London, United Kingdom; ² Takeda Europe R&D, London, United Kingdom

PDB32

ECONOMIC EVALUATION OF THE LAPTOP-STUDY RESULTS
Högy B¹, Janka HU², Huppertz E^3
1Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Germany; ² Klinikum Bremen-Nord, Bremen, Germany; ³ Aventis Pharma Deutschland GmbH, Berlin, Germany

PDB33

COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES IN A FRENCH SETTING
Palmer AJ¹, Valentine WJ¹, Roze S¹, Chen R², Gabriel S³, Bregman B⁴, Mehin N³, Parving HH^5
1CORE Center for Outcomes Research, Binningen, Switzerland; ² Bristol-Myers Squibb, Princeton, NJ, USA; ³ Sanofi-Aventis, Bagneux, France; ⁴ Bristol-Myers Squibb, Rueil-Malmaison, France; ⁵ Steno Diabetes Center, Gentofte, Denmark

PDB34

DIABETES PREVALENCE AND DIRECT MEDICAL COST ANALYSIS PER YEAR FROM 1997 TO 2001 IN TAIWAN
Tarn TH¹, Lin WA^2
1Taipei City Hospital, Taipei, Taiwan; ² National defence medical center, Taipei, Taiwan

PDB35

THE COST OF DIABETES MELLITUS IN SPAIN
Rubio-Terrés C¹, Faure E², Poyato F³, Del Castillo A³, González P^3
1HERO Consulting, Madrid, Spain; ² Hospital Clínico, Zaragoza, Spain; ³ Pfizer S.A., Spain, Alcobendas, Madrid, Spain

PDB36

COST OF TYPE 2 DIABETES MELLITUS IN HONG KONG CHINESE
Chan BS¹, Tsang M², Lee VW¹, Lee KK^1
1The Chinese University of Hong Kong, Hong Kong, China; ² United Christian Hospital, Hong Kong, China

PDB37

COSTS OF STAYS OF CARDIOVASCULAR EVENTS OF DIABETIC PATIENTS IN THE FRENCH HOSPITALS
Colin X¹, Lafuma A¹, Gueron B^2
1Cemka Eval, Bourg-la-Reine, Hauts de Seine, France; ² Pfizer, Paris, France

PDB38

ANALYSIS OF THE COST OF DIABETES TREATMENT IN BULGARIA
Ivanova D A¹, Ignatova S R², Popov V V¹, Petrova I G^1
1Faculty of Pharmacy at the Medical University in Sofia, Sofia, Bulgaria; ² National Health Insurance Fund, Bulgaria, Sofia, Bulgaria

PDB39

EVALUATION OF THE COST-UTILITY OF INSULIN DETEMIR COMPARED TO INSULIN GLARGINE, BOTH IN COMBINATION WITH INSULIN ASPART IN TYPE 1 DIABETES IN GERMANY AND AUSTRIA
Roze S¹, Wittrup-Jensen KU², Valentine WJ¹, Palmer AJ^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² Novo Nordisk Pharma, Mainz, Germany

PDB40

COST-UTILITY ANALYSIS IN A USA SETTING OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES
Palmer AJ¹, Chen R², Valentine WJ¹, Roze S¹, Gabriel S³, Mehin N³, Bregman B⁴, Rodby R^5
1CORE Center for Outcomes Research, Binningen, Switzerland; ² Bristol-Myers Squibb, Princeton, NJ, USA; ³ Sanofi-Aventis, Bagneux, France; ⁴ Bristol-Myers Squibb, Rueil-Malmaison, France; ⁵ Rush University Medical Center, Chicago, IL, USA

PDB41

DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA) AND HEALTHCARE RESOURCE USE AND PRODUCTIVE LOSSES
Currie CJ¹, Cawley S², Morgan CL¹, McEwan P¹, Price P¹, Peters JR³, Covington M^4
1Cardiff University, Cardiff, Wales, United Kingdom; ² NHS Wales, Cardiff, Wales, United Kingdom; ³ University Hospital of Wales, Cardiff, Wales, United Kingdom; ⁴ Eli Lilly and Company, Indianapolis, IN, USA

PDB42

WITHDRAWN

PDB43

SHOULD WE LOOK FOR A NEW APPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?
Sieradzki J¹, Kinalska I², Niewada M³, Faluta T⁴, Czech M⁴, Latek M⁵, Wilkins A⁴, Szczepanski M⁴, Pachocki R^4
1Medical College, Jagiellonian University in Krakow, Krakow, Poland; ² Medical University in Bialystok, Bialystok, Poland; ³ Medical University of Warsaw, Warsaw, Poland; ⁴ Servier Poland, Warsaw, Poland; ⁵ Warsaw School of Economics, Warszawa, Mazowieckie, Poland

PDB44

USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS
Sicras A¹, Navarro R¹, Xavier F¹, Ruíz R¹, Rejas J², Fernández J^2
1Badalona Servicios Asistenciales,SA, Badalona, Barcelona, Spain; ² Pfizer Spain, Alcobendas/Madrid, Spain

PDB45

PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTHCARE COSTS IN U.S. PATIENTS WITH TYPE 2 DIABETES: RESULTS FROM A NATIONAL SURVEY STUDY
Shenolikar R, Balkrishnan R
Ohio State University College of Pharmacy, Columbus, OH, USA

PDB46

WITHDRAWN

PDB47

TYPE 2 DIABETES AND GLYCEMIC CONTROL IN GERMANY
Yurgin N¹, Secnik K¹, Lage MJ^2
1Eli Lilly and Company, Indianapolis, IN, USA; ² HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PDB48

KNOWLEDGE ABOUT INSULIN AND WILLINGNESS TO USE IT INFLUENCE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ONLY TREATED WITH ORAL ANTIDIABETIC DRUGS – A GERMAN SURVEY
Stridde E¹, Göke B², Huppertz E³, Weitkunat R², Crispin A^2
1Pfizer Pharma GmbH, Karlsruhe, Germany; ² Ludwig-Maximilians-Universität, München, Germany; ³ Aventis Pharma Deutschland GmbH, Berlin, Germany

PDB49

PATTERNS OF BLOOD GLUCOSE MONITORING IN RELATION TO GLYCAEMIC CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES IN THE UK
Secnik K¹, Yurgin N¹, Lage MJ², McDonald-Everett C^1
1Eli Lilly and Company, Indianapolis, IN, USA; ² HealthMetrics Outcomes Research, LLC, Groton, CT, USA

PDB50

MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES
Annemans L¹, Lamotte M¹, Caro JJ², Lavaud V³, Nicholls C⁴, McEwan P^5
1IMS Health, Brussels, Belgium; ² Caro Research, Concord, MA, USA; ³ Sanofi-aventis, Bagneux, France; ⁴ Sanofi-aventis, Guildford, Surrey, United Kingdom; ⁵ Cardiff University, Cardiff, United Kingdom

PDB51

EVALUATING INTERVENTIONS ALONG THE COURSE OF DISEASE: MODELING DIABETES AND ITS MACROVASCULAR COMPLICATIONS
Feenstra TL, Hoogenveen R, Bos G, Baan C
National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands

PDB52

TYPE 2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATES AND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
Palmer AJ¹, Valentine WJ¹, Minshall ME², Roze S^1
1CORE - Center for Outcomes Research, Binningen, Basel, Switzerland; ² CORE - USA, LLC, Fishers, IN, USA

PDB53

INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL
Walzer S, Maxion-Bergemann S, Bergemann R, Casciano RN, Mueller E
Analytica International, Loerrach, Germany

PDB54

WITHDRAWN

PDB55

MEASURING QUALITY OF LIFE WITH EQ-5D IN AN AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH DIABETES MELLITUS
Seereiner S¹, Rakovac I¹, Habacher W¹, Fritz C¹, Beck P¹, Semlitsch B², Haas H², Pieber TR^1
1Joanneum Research, Graz, Styria, Austria; ² University Hospital Graz, Graz, Styria, Austria

PDB56

AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND VERSUS METFORMIN+GLIMEPIRIDE IN TYPE 2 PATIENTS WITH INADE-QUATE GLYCAEMIC CONTROL
Hammer M¹, Valentine WJ², Wittrup-Jensen KU¹, Palmer AJ^2
1Novo Nordisk A/S, Bagsvaerd, Denmark; ² CORE Center for Outcomes Research, Binningen, Switzerland

PDB57

TREATMENT SATISFACTION AND QUALITY OF LIFE WITH AN EARLY INSULINIZATION STRATEGY WITH INSULIN GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN THE MANAGEMENT OF TYPE-2 DIABETES: THE CANADIAN INSIGHT STUDY
Houlden R¹, Harris S², Yale JF³, Sauriol L⁴, Dempsey E⁵, Gerstein HC^6
1Queen's University, Kingston, ON, Canada; ² Thames Valley Family Practice, London, ON, Canada; ³ McGill University/ CUSM Royal Victoria Hospital, Montreal, QC, Canada; ⁴ Sanofi-aventis, Laval, QC, Canada; ⁵ Aventis Pharma Canada, Laval, AB, Canada; ⁶ McMaster University, Hamilton, ON, Canada

PDB58

DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA) AND HEALTH-RELATED UTILITY (EQ5D)
Currie CJ¹, Covington M², McEwan P¹, Price P¹, Morgan CL¹, Cawley S³, Peters JR^4
1Cardiff University, Cardiff, Wales, United Kingdom; ² Eli Lilly and Company, Indianapolis, IN, USA; ³ NHS Wales, Cardiff, Wales, United Kingdom; ⁴ University Hospital of Wales, Cardiff, Wales, United Kingdom

PDB59

DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT PROFILING BASED ON PATIENT ATTITUDE TOWARDS INSULIN
Arnould B¹, Consoli S², Martinez L³, Wong O⁴, Yomtov B⁵, Simon D⁶, Monnier L⁷, Beillat M⁸, Benmedjahed K⁹, Fleury F¹⁰, Gueron B^8
1Mapi Values, Lyon, Rhone, France; ² Georges Pompidou European Hospital, Paris, France; ³ Private Practice, Bois D'arcy, France; ⁴ Private practice, Paris, France; ⁵ Henri Mondor, Creteil, France; ⁶ Pitié Salpétrière, Paris, France; ⁷ CH Lapeyronie, Montpellier, France; ⁸ Pfizer, Paris, France; ⁹ Mapi Values, Lyon, France; ¹⁰ Sanofi Aventis, Gentilly, France

PDB60

DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE BARRIER SURVEY IN PATIENTS WITH CHRONIC CONDITIONS
Yu-Isenberg KS¹, Espindle DM², Skinner EP¹, Weaver MB¹, Olson PS¹, Hahn SR^3
1GlaxoSmithKline, RTP, NC, USA; ² Mapi Values USA, Boston, MA, USA; ³ Albert Einstein College of Medicine, Bronx, NY, USA

PDB61

PERCEIVED HEALTH CARE INFORMATION ON DIABETES: MEASUREMENT OF PATIENT SATISFACTION
Carmosino G¹, Zerbini O¹, Comarella L², Morelli P², Balestri M³, Brioschi A^3
1CROM Srl Contract Research Organisation Medical and Pharmaceutical Projects, Verona, Italy; ² CROS NT Srl, Verona, Italy; ³ Roche Diagnostics, Monza, Italy

PDB62

TREATMENT SATISFACTION IN SUBJECTS WITH TYPE 2 DIABETES RECEIVING INSULIN GLARGINE
Davies M¹,, Gomis R², Sharplin P³, Mechiche S⁴, Storms F⁵, on behalf of the AT.LANTUS Study Group
¹University Hospitals of Leicester, Leicester, United Kingdom; ² Hospital Clínic de Barcelona, Barcelona, Spain; ³ sanofi-aventis, Auckland, New Zealand; ⁴ sanofi-aventis, Paris, France; ⁵ Diabetes Centrum, Bilthoven, Netherlands

.........................TOP

PEY1

ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)
Maurel F¹, Hieke K², Negrini C³, Priol G¹, Berdeaux G⁴, Le Pen C^1
1Aremis, Neuilly sur Seine, Hauts de Seine, France; ² Neos Health, Binningen, Switzerland; ³ PBE-Consulting, Verona, Italy; ⁴ Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY2

USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES
Nordmann JP¹, Berdeaux G^2
1Hospital XV-XX, Paris, Paris, France; ² Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY3

INTRA-OCULAR PRESSURE (IOP) CONTROL OF LATANOPROST AND TRAVOPROST MONOTHERAPY IN DAILY PRACTICE
Denis P¹, Devaux M², Launois R², Berdeaux G^3
1Hôpital Edouard Herriot, Lyon, Rhone, France; ² REES France, Paris, Paris, France; ³ Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY4

EVALUATION OF INCREMENTAL EFFICACY OF LATANOPROST-TIMOLOL IN THE TREATMENT OF PRIMARY OPEN-ANGLE GLAUCOMA USING RETROSPECTIVE ANALYSIS OF THE GLASGOW ROYAL INFIRMARY GLAUCOMA DATABASE
Montgomery D¹, Lazaridou MN¹, Ho WO¹, Jaberoo D¹, Mychaskiw MA^2
1Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom; ² Pfizer, Inc, New York, NY, USA

PEY5

COMPARING EFFICACY OF PROSTAGLANDIN ANALOGUES FOR CONTROLLING INTRA-OCULAR PRESSURE (IOP): RESULTS OF A META-ANALYSIS
Mimaud V¹, Lafuma A², Khoshnood B², Berdeaux G^3
1Cemka-Eval, Bourg-la-Reine, Hauts de Seine, France; ² Cemka Eval, Bourg-la-Reine, Hauts de Seine, France; ³ Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY6

A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE ACETATE IN WET AGE-RELATED MACULAR DEGENERATION
Deschaseaux-Voinet C¹, Lafuma A¹, Berdeaux G^2
1Cemka Eval, Bourg-la-Reine, Hauts de Seine, France; ² Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY7

NUMBER OF TREATABLE EYES WITH WET SUB-FOVEAL AGE-RELATED MACULAR DEGENARATION (ARMD) : USE OF DIRECT STANDARDIZATION AND MARKOV MODEL
Moore N¹, Blin P¹, Berdeaux G^2
1CHU de Bordeaux - Université Victor Segalen - INSERM U657, Bordeaux, Gironde, France; ² Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY8

EYE ADVERSE EFFECTS ASSOCIATED WITH POLYVINYL ALCOHOL TEAR DROPS AFTER LASER ASSISTED SUBEPITHELIAL KERATECTOMY (LASEK)
Flores C¹, Luque L², Gomez MC³, Avila L⁴, Natera MA^5
1Instituto de Investigaciones Oftalmológicas, Sevilla, Sevilla, Spain; ² Consultorio de Burguillos, Burguillos, Sevilla, Spain; ³ ZBS Velez Norte, Velez Malaga, Malaga, Spain; ⁴ ZBS Axarquía oeste, Almachar, Malaga, Spain; ⁵ ZBS Axarquía Oeste, Benamargosa, Malaga, Spain

PEY9

COST-EFFECTIVENESS MODEL FOR AGE-RELATED MACULAR DEGENERATION: COMPARING MACUGEN TO VISUDYNE
Earnshaw SR¹, Javitt JC², Zlateva GP³, Pleil AM⁴, Graham CN¹, Brogan AJ¹, Shah SN⁵, Adamis AP^6
1RTI Health Solutions, Research Triangle Park, NC, USA; ² Wilmer Ophthalmological Institute, Baltimore, MD, USA; ³ Pfizer Global Pharmaceuticals, New York, NY, USA; ⁴ Pfizer Incorporated, San Diego, CA, USA; ⁵ Pfizer, Inc, New York, NY, USA; ⁶ Eyetech Pharmaceuticals, New York, NY, USA

PEY10

COMBIGAN – COST-MINIMIZATION ANALYSIS OF BRIMONIDINE/TIMOLOL FIXED COMBINATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA
Poulsen PB¹, Buchholz P², Walt J^3
1MUUSMANN Research & Consulting, Kolding, Denmark; ² Allergan, Ettlingen, Germany; ³ Allergan, Irvine, CA, USA

PEY11

COST-EFFECTIVENESS MODEL FOR AGE-RELATED MACULAR DEGENERATION: COMPARING EARLY AND LATE MACUGEN TREATMENT
Earnshaw SR¹, Javitt JC², Zlateva GP³, Pleil AM⁴, Graham CN¹, Brogan AJ¹, Shah SN⁵, Adamis AP^6
1RTI Health Solutions, Research Triangle Park, NC, USA; ² Wilmer Ophthalmological Institute, Baltimore, MD, USA; ³ Pfizer Global Pharmaceuticals, New York, NY, USA; ⁴ Pfizer Incorporated, San Diego, CA, USA; ⁵ Pfizer, Inc, New York, NY, USA; ⁶ Eyetech Pharmaceuticals, New York, NY, USA

PEY12

PHARMACOECONOMIC ANALYSIS OF LATANOPROST VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA IN SPAIN
Ortega P, Soto J, Fernández-Arias I, De Miguel V
Pfizer Spain, Alcobendas, Madrid, Spain

PEY13

COSTS AND CONSEQUENCES OF ENDOPHTHALMITIS : RESULTS FROM THE NATIONAL ENDOPHTALMITIS SURVEY
Berdeaux G¹, Salvanet-Bouccara A², Grillon S², Lafuma A³, Deschaseaux-Voinet C^3
1Alcon France SA, Rueil-Malmaison, Hauts de Seine, France; ² CHR Villeneuve Saint Georges, Villeneuve Saint Georges, Val de Marne, France; ³ Cemka Eval, Bourg-la-Reine, Hauts de Seine, France

PEY14

IMPACT OF VISUAL ACUITY ON MEDICAL AND NON-MEDICAL COSTS IN PATIENTS SUFFERING FROM WET AGE-RELATED MACULAR DEGEN-ERATION IN FRANCE, GERMANY AND ITALY
Benhaddi H¹, Hieke K², Negrini C³, Priol G¹, Berdeaux G⁴, Le Pen C^1
1Aremis, Neuilly sur Seine, Hauts de Seine, France; ² Neos Health, Binningen, Switzerland; ³ PBE-Consulting, Verona, Italy; ⁴ Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY15

COST OF ENDOPHTHALMITIS : A NATIONWIDE APPROACH
Colin X¹, Lafuma A¹, Berdeaux G^2
1Cemka Eval, Bourg-la-Reine, Hauts de Seine, France; ² Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY16

THE PREVALENCE AND COST OF TREATMENT OF PATIENTS TAKING ANTIGLAUCOMA AGENTS FOR GLAUCOMA OR OCULAR HYPERTENSION IN FRANCE
De Pouvourville GA¹, Solesse de Gendre A², Beillat M^2
1INSERM, Le Kremlin Bicêtre, France; ² Pfizer, Paris, France

PEY17

MODELING TREATMENTS FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE RELATED MACULAR DEGENERATION: COST-EFFECTIVENESS METHODS
Earnshaw SR¹, Javitt JC², Graham CN¹, Brogan AJ¹, Zlateva GP³, Pleil AM⁴, Shah SN⁵, Adamis AP^6
1RTI Health Solutions, Research Triangle Park, NC, USA; ² Wilmer Ophthalmological Institute, Baltimore, MD, USA; ³ Pfizer Global Pharmaceuticals, New York, NY, USA; ⁴ Pfizer Incorporated, San Diego, CA, USA; ⁵ Pfizer, Inc, New York, NY, USA; ⁶ Eyetech Pharmaceuticals, New York, NY, USA

PEY18

WITHDRAWN

PEY19

METHODS FOR A POPULATION-BASED INTERNATIONAL STUDY ON THE BURDEN OF ILLNESS OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Soubrane G¹, Monés J², Cruess A³, Lotery A⁴, Pauleikhoff D⁵, Buggage R⁶, Pena B⁶, Zlateva G^6
1Clinique Ophtalmologique Universitaire, Creteil, France; ² Instituto de Microcirugia Ocular de Barcelona, Barcelona, Spain; ³ Dalhousie University, Halifax, Nova Scotia, Canada; ⁴ University of Southampton, Southamton, United Kingdom; ⁵ Augenarztpraxis des St. Franziskus-Hospital, Münster, Germany; ⁶ Pfizer Global Pharmaceuticals, New York, NY, USA

PEY20

IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION
Maurel F¹, Hieke K², Negrini C³, Priol G¹, Berdeaux G⁴, Le Pen C^1
1Aremis, Neuilly sur Seine, Hauts de Seine, France; ² Neos Health, Binningen, x, Switzerland; ³ PBE-Consulting, Verona, x, Italy; ⁴ Alcon France SA, Rueil-Malmaison, Hauts de Seine, France

PEY21

UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE IN THE UK
Buchholz P¹, Steeds C², Stern LS³, Wiederkehr DP³, Doyle JJ³, Katz LM³, Figueiredo FC^4
1Allergan, Ettlingen, Germany; ² Consultant, Motherwell, United Kingdom; ³ Analytica International, New York, NY, USA; ⁴ Royal Victoria Infirmary, Newcastle Upon Tyne, England

PEY22

DEVELOPMENT AND VALIDATION OF A COMPREHENSIVE PAINFUL SYMPTOM CHECKLIST ALLOWING TO PROVIDE A COMPLETE DESCRIPTION OF PAIN IN OPHTHALMIC DISEASES
Arnould B¹, Benmedjahed K², Brouquet Y³, Bassols A³, Colin J^4
1Mapi Values, Lyon, Rhone, France; ² Mapi Values, Lyon, France; ³ Chauvin Bausch and Lomb, Montpellier, France; ⁴ Pellegrin Hospital, Bordeaux, France

.........................TOP

PHP1

A COMPARISON OF FREQUENTIST AND BAYESIAN STATISTICAL APPROACHES IN COST-BENEFIT ANALYSIS
Blizzard J¹, Michels J², Reeder CE², Lingle EW², Schulz RM², Bradford WD^3
1Wingate University, Wingate, NC, USA; ² University of South Carolina, Columbia, SC, USA; ³ Medical University of South Carolina, Charleston, SC, USA

PHP2

IMPLEMENTATION OF AN EVIDENCE BASED GUIDELINE FOR CLINICAL NUTRITION IN A 500 BED HOSPITAL IN NORTHERN GERMANY: INFLUENCE ON DIRECT COST FOR CLINICAL NUTRITION
Steinhausen K, Gohlke A, Goeke T, Fischer FJ
Schellen and Partner, Düsseldorf, Germany

PHP3

ECONOMIC IMPACT OF A DEVICE FOR PREPARING STERILE SOLUTIONS IN THE MT. SINAI HOSPITAL PHARMACY
Ellegard B¹, Meyer J¹, Caliendo G¹, Herdman M², Romera B^3
1The Mount Sinai Medical Center, New York, NY, USA; ² 3D Health Research, Barcelona, Barcelona, Spain; ³ 3D Health Research, Barcelona, Spain

PHP4

ECONOMIC COMPARISON OF TWO XENETIX® 300 PRESENTATIONS
Castelli C¹, Lamarsalle L², Vainchtock A², Woessmer B^3
1Institut Universitaire de Recherche Clinique Laboratoire Epidemiologie et Biostatistique, Montpellier cedex 05, France; ² IMS Health - GYD institut, Lyon, France; ³ GUERBET, Roissy CDG Cedex, France

PHP5

COST OF SEVERE BLUNT TRAUMA IN THE UNITED KINGDOM
Porter K¹, Lovatt B², Wilkinson A^2
1Selly Oak Hospital, Birmingham, United Kingdom; ² Vision Healthcare Consultancy Ltd, Surrey, United Kingdom

PHP6

DRUG PRICE INDICES 1980–2004 IN FINLAND
Hahl J¹, Aaltonen S², Linden K¹, Jormanainen V^1
1GlaxoSmithKline, Espoo, Finland; ² Pharma Industry Finland, Helsinki, Finland

PHP7

MANAGING ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS: EMERGENCY DEPARTMENT AND INPATIENT HOSPITAL RESOURCE USE AND COSTS
O'Brien JA¹, Pitoniak-Morse C¹, Jacobs LM^2
1Caro Research Institute, Concord, MA, USA; ² University of Connecticut Medical School, Farmington, CT, USA

PHP8

RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY
Segerer C, Wagner B, Wittmann G, Schramm W, Berger K
University Hospital of Munich, Munich, Bavaria, Germany

PHP9

PHARMACEUTICAL CARE IN GREECE: A CITIZEN SATISFACTION SURVEY
Geitona M¹, Zavras D², Kyriopoulos J^3
1University of Thessaly, Athens, Greece; ² Hellenic Association for Pharmacoeconomics, Athens, Greece; ³ National School of Public Health, Athens, Greece

PHP10

THE IMPACT OF MEDICARE MANAGED CARE ON USE OF VA PHARMACY SERVICES
Morgan RO¹, Hasche J¹, Osemene N², Byrne M³, Sundaravaradan R¹, Wei I¹, Petersen L¹, Johnson M^1
1Houston Center for Quality of Care and Utilization Studies, Houston, TX, USA; ² Texas Southern University, Houston, TX, USA; ³ University of Miami Miller School of Medicine, Miami, FL, USA

PHP11

AN INTRODUCTION TO HEALTH TOURISM AND MEDICAL TOURISM
Carrera P
University of Heidelberg, Heidelberg, Germany

PHP12

PRICING POLICIES FOR THE PHARMACEUTICAL MARKET - AN INTERNATIONAL PERSPECTIVE
Ilgin Y, Eisen R
Johann Wolfgang Goethe University, Frankfurt am Main, Germany

PHP13

MULTIPLE APPRAISAL OF DRUGS IN THE UK HEALTH CARE SYSTEM
Hutton J¹, Pang F^2
1United BioSource Corporation, London, United Kingdom; ² Abbott Laboratories Ltd, Maidenhead, Berkshire, United Kingdom

PHP14

OPPS PHARMACY HANDLING COSTS: POLICY IMPLICATIONS
Baker JJ¹, Ziskind MA^2
1The Resource Group, Dallas, TX, USA; ² Centocor, Inc, Horsham, PA, USA

PHP15

THE CONSUMPTION OF DRUGS FINANCED BY THE SPANISH NATIONAL HEALTH SYSTEM AND THE IMPACT OF PHARMACOVIGILANT ACTIONS
Gaspar MD, Modamio P, Lastra CF, Marino EL
University of Barcelona, Barcelona, Spain

PHP16

ESTIMATING THE COST SAVINGS AND RATIONAL USE EFFECTS OF IMPLEMENTING AN ESSENTIAL MEDICINES LIST
Hamidi S¹, Khan M¹, Babo D¹, Culbertson R¹, Rice J¹, Younis M^2
1Tulane University, New Orleans, LA, USA; ² Jackson State University, Jackson, MS, USA

PHP17

EFFECTS OF GENERIC SUBSTITUTION ON THE DEVELOPMENT OF PHARMACEUTICAL EXPENDITURES DURING THE PERIOD JANUARY 1998 TO MAY 2005
Andersson K¹, Bergström G¹, Petzold M², Lönnroth K¹, Carlsten A^1
1Göteborg University, Göteborg, Sweden; ² Nordic School of Public Health, Göteborg, Sweden

PHP18

GEOGRAPHICAL INFORMATION SYSTEM (GIS) ANALYSIS OF SMALL AREA INEQUALITIES IN DRUG EXPENDITURES IN HUNGARY
Boncz I¹, David T¹, Takacs E¹, Sebestyen A^2
1National Health Insurance Fund Administration (OEP), Budapest, Hungary; ² National Health Insurance Fund Administration (OEP), Pécs, Hungary

PHP19

PRESCRIPTION DRUGS AND ANNUAL BENEFIT CAPS – DO PATIENTS ANTICIPATE EXCEEDING THE CAP?
Hsu J¹, Huang J¹, Price M¹, Fung V¹, Fireman B¹, Brand R^2
1Kaiser Permanente, Oakland, CA, USA; ² University of California, San Francisco, San Francisco, CA, USA

PHP20

GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES
Palmer WN, Neale S, Morris C
Palmer D'Angelo Consulting, Ottawa, ON, Canada

PHP21

PHARMACEUTICAL POLICY IN GREECE: RECENT DEVELOPMENTS AND THE ROLE OF PHARMACOECONOMICS
Vandoros C, Geitona M, Kontozamanis V, Karokis A
Hellenic Association for Pharmacoeconomics, Athens, Greece

PHP22

EFFECTS OF DECENTRALIZED RESPONSIBILITY FOR COSTS OF OUTPATIENT PRESCRIPTION DRUGS ON THE PHARMACEUTICAL COST DEVELOPMENT IN SWEDEN
Bergstrom G¹, Andersson K¹, Carlsten A¹, Karlberg I¹, Petzold M², Lönnroth K^1
1Göteborg university, Göteborg, Sweden; ² Nordic School of Public Health, Göteborg, Sweden

PHP23

A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS IN THE NORDIC COUNTRIES
Kristensen FKO, Sverre JM, Holm LB
PharmEcon AS, Asker, Norway

PHP24

A SYSTEMATIC REVIEW OF THE EUROPEAN PHARMACEUTICAL MARKET AND THE IMPACT OF EUROPEAN UNION REGULATION AND JURISDICTION
Van Ginneken EJ, Schreyögg J, Gericke CA, Busse R
Berlin University of Technology, Berlin, Germany

PHP25

USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS
Yuen EJ, Maio V, Louis DZ, Rabinowitz C, Robeson M, Smith KD
Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

PHP26

ADHERENCE INDEX OF PERFORMANCE - A NEW METHOD AND TOOL FOR ONGOING EVALUATION OF MEDICATION ADHERENCE IMPROVEMENT INITIATIVES
Day D
Pfizer, New York, NY, USA

PHP27

PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)
Van Wilder P, Verplanken P, Bormans V
S.M.A.R.T, Zaventem, Belgium

PHP28

ECONOMIC EVALUATION OF NEW TECHNOLOGIES IN THE HOSPITAL SETTING: THE EXPERIENCE OF THE AZIENDA OSPEDALIERA DI VERONA, ITALY
Marini P, Filippi C, Ghirlanda G, Perilli V, Scroccaro G
Azienda Ospedaliera di Verona, Verona, Italy, Italy

PHP29

REIMBURSEMENT OF HIGH-PRICED NEW EMERGING MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL CARE SYSTEM
Hessel FP, Greß S, Wasem J
University of Duisburg-Essen, Essen, NRW, Germany

PHP30

PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTHCARE SYSTEM IN SAUDI ARABIA
Alsultan MS, Al-Sabhan JF
King Saud University College of Pharmacy, Riyadh, Riyadh, Saudi Arabia

PHP31

CHARGES FOR HOSPITAL ADMISSIONS ATTRIBUTABLE TO HEALTH DISPARITIES FOR AFRICAN AMERICAN PATIENTS IN SOUTH CAROLINA DURING 1998-2002
Chumney EC, Simpson K, Mauldin P
Medical University of South Carolina, Charleston, SC, USA

PHP32

COMBINING PHARMACY AND HOSPITAL DATA IN A RISK ADJUSTMENT MODEL
Yuen EJ¹, Smith KD¹, Maio V¹, Donatini A², Robeson M¹, Rabinowitz C¹, Louis DZ¹, Taroni F^3
1Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; ² Azienda USL di Parma, Parma, Emilia Romagna, Italy; ³ Regione Emilia Romagna, Bologna, Emilia Romagna, Italy

PHP33

USE OF PHARMACOECONOMICS FOR CREATION OF THE STATE FORMULARY IN UKRAINE
Zaliska O¹, Parnovsky BL^2
1Lviv National Medical University, Lviv, Ukraine; ² Lviv National Medical University named Danylo Galitsky, Lviv, Ukraine

PHP34

EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE: EVIDENCE FROM CHINA
Yi Y, Maynard A
University of York, York, United Kingdom

PHP35

AGE AND GENDER IN PHARMACEUTICAL EXPENDITURE: A TOOL FOR RISK CALCULATION
Gilabert i Perramon A, Magem Luque D
Catalan Health Service, Barcelona, BARCELONA, Spain

PHP36

WITHDRAWN

PHP37

PHARMACOECONOMIC CLAIMS IN PRESCRIPTION DRUG ADVERTISEMENTS IN FINNISH MEDICAL JOURNALS
Norjamäki A¹, Martikainen J², Turunen J², Kivioja A^1
1Ministry of Social Affairs and Health, Helsinki, Finland; ² University of Kuopio, Kuopio, Finland

PHP38

BELIEFS ABOUT MEDICINES AMONG SWEDISH PHARMACY EMPLOYEES
Jörgensen T, Andersson K, Mårdby AC
Göteborg University, Göteborg, Sweden

PHP39

PUBLIC FUNDING OF DRUGS FOR ORPHAN DISEASES
Hughes D
University of Wales, Bangor, Gwynedd, United Kingdom

PHP40

THE IMPACT ON DECISION-MAKING OF CHANGING COST-EFFECTIVENESS OF HEALTH TECHNOLOGIES OVER TIME
Pang F¹, Tolley K^2
1Abbott Laboratories Ltd, Maidenhead, Berkshire, United Kingdom; ² MAPI VALUES, Bollington, United Kingdom

PHP41

EXAMINING THE QUALITY OF HEALTH ECONOMIC ANALYSES SUBMITTED TO THE REIMBURSEMENT AGENCIES IN SWEDEN AND FINLAND – A CROSS COUNTRY COMPARISON
Engstrom A¹, Kivioja A^2
1Pharmaceutical Benefits Board, Solna, Sweden; ² Ministry of Social Affairs and Health, Helsinki, Finland

PHP42

PAYMENT FOR PHARMACY HANDLING COSTS IN THE HOPD: 2006 REIMBURSEMENT IMPLICATIONS
Baker JJ¹, Panarites CJ^2
1The Resource Group, Dallas, TX, USA; ² Scios, Inc, Fremont, CA, USA

PHP43

IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS
Layton MR¹, Chadbunchachai S¹, Thinkhamrop B¹, Tangcharoensathien V², Wertheimer AI^3
1Khon Kaen University, Khon Kaen, Thailand; ² International Health Policy Program, Nonthaburi, Thailand; ³ Temple University, Philadelphia, PA, USA

PHP44

COST AVOIDANCE OF CLINICAL PHARMACIST INTERVENTIONS AT A UNIVERSITY TEACHING HOSPITAL
Howe AM
Grady Health System, Altanta, GA, USA

PHP45

APPRAISAL OF FIVE NEW OUT-OF-HOURS (OOH) PRIMARY CARE CENTRES IN THE PARISIAN REGION: “MAISONS MÉDICALES DE GARDE (MMG)”
Lemasson H¹, Jasso Mosqueda J², Chicoye A^2
1AREMIS Consultants, Neuilly Sur Seine, Ile de France, France; ² AREMIS Consultants, Neuilly Sur Seine, France

PHP46

DEFINING COMPLIANCE/ADHERENCE AND PERSISTENCE: ISPOR SPECIAL INTEREST WORKING GROUP
Burrell A¹, Wong P², Ollendorf D³, Fuldeore M⁴, Roy A⁵, Fairchild C⁶, Cramer J^7
1Sanofi-Aventis, Bridgewater, NJ, USA; ² Good Samaritan Hospital, Dayton, OH, USA; ³ PharMetrics, Inc, Watertown, MA, USA; ⁴ Walgreens Health Services, Deerfield, IL, USA; ⁵ West Virginia University, Morgantown, WV, USA; ⁶ Alcon Laboratories, Fort Worth, TX, USA; ⁷ Yale University School of Medicine, West Haven, CT, USA

PHP47

EVALUATION OF THE RELATIONSHIP BETWEEN PHARMACEUTICAL PRODUCT PRICE AND HEALTH-RELATED QUALITY OF LIFE USING WHOLESALE ACQUSITION COST AND AVERAGE EFFECT SIZE
Murawski MM¹, Mychaskiw MA^2
1Purdue University, West Lafayette, IN, USA; ² Pfizer, Inc, New York, NY, USA

PHP48

A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING.
Yuwaree V, Rojsutee S, Thavorncharoensap M
Mahidol University, Rajathevi, Bangkok, Thailand

.........................TOP

PMH1

COST EFFECTIVENESS OF ESCITALOPRAM IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)
Walker JH¹, Bereza BG¹, Hemels M², Le Melledo JM³, Iskedjian M¹, Einarson T^4
1PharmIdeas Research & Consulting Inc, Oakville, ON, Canada; ² H. Lundbeck A/S, Paris, France; ³ University of Alberta, Edmonton, AB, Canada; ⁴ University of Toronto, Toronto, ON, Canada

PMH2

WITHDRAWN

PMH3

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GROWN-UPS: ADMINISTRATIVE DATA ON CO-EXISTING CONDITIONS
Schlander M¹, Schwarz O¹, Trott GE¹, Viapiano M², Bonauer N^2
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany; ² Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany

PMH4

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS: MENTAL HEALTH AND PHYSICAL CO-MORBIDITY IN NORDBADEN / GERMANY
Schlander M¹, Schwarz O¹, Trott GE¹, Viapiano M², Bonauer N^2
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany; ² Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany

PMH5

A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
Tilden D¹, Richardson R¹, Nyhus K², Robinson P¹, Cottrell S^1
1M-TAG, A division of IMS Health Economics and Outcomes Research, London, United Kingdom; ² Eli Lilly Norway, Oslo, Norway

PMH6

TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): ARE U.S. COST-EFFECTIVENESS FINDINGS BASED UPON THE MTA STUDY RELEVANT TO MENTAL HEALTH CARE POLICY MAKERS IN GERMANY?
Schlander M¹, Schwarz O¹, Trott GE¹, Taylor E², Jensen PS³, Garcia JA³, Glied S³, Crowe M^3
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany; ² King's College, London, United Kingdom; ³ Columbia University, New York, NY, USA

PMH7

THE BAD STUDY: SOCIAL AND ECONOMIC BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN ITALY
Lopatriello S¹, Zuddas A², Molteni M³, Masi G⁴, Maschietto D⁵, Berto P^1
1Pbe consulting, Verona, Italy; ² Università di Cagliari, Cagliari, Italy; ³ IRCCS Eugenio Medea, Bosisio Parini (LC), Italy; ⁴ IRCCS Stella Maris, Calambrone (PI), Italy; ⁵ Ospedale di san Donà di Piave, San Donà di Piave, Italy

PMH8

THE HEATLH–RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
Hakkaart L¹, Zwirs B², Bouwmans C¹, Buitelaar J³, Schulpen T², Veraart C⁴, Rutten F^5
1Erasmus MC, Rotterdam, ZH, Netherlands; ² University Medical Centre Utrecht, Utrecht, Netherlands; ³ University Medical Centre st Radbout Nijmegen, Nijmegen, Netherlands; ⁴ Elli Lilly, Houten, Netherlands; ⁵ Erasmus MC, Rotterdam, Netherlands

PMH9

STIMULANT MEDICATION TREATMENT OF ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER IS ASSOCIATED WITH DECREASED EMERGENCY DEPARTMENT COSTS AND UTILIZATION: POPULATION-BASED STUDY
Katusic SK¹, Barbaresi WJ¹, Colligan RC¹, Kemner J², Weaver AL¹, Leibson CL^1
1Mayo Clinic College of Medicine, Rochester, MN, USA; ² McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA, USA

PMH10

A MODELED ECONOMIC EVALUATION COMPARING ATOMOXETINE WITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS
Laing A¹, Cottrell S¹, Robinson P¹, Veraart C², Tilden D¹, Aristides M^1
1M-TAG, A division of IMS Health Economics and Outcomes Research, London, United Kingdom; ² Eli Lilly, Houten, Netherlands

PMH11

WITHDRAWN

PMH12

THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY
Schlander M, Schwarz O
Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany

PMH13

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS: SF-6D UTILITIES FROM SF-36 SCORES IN A RANDOMISED TRIAL OF ATOMOXETINE
Laing A, Aristides M
M-TAG, A division of IMS Health Economics and Outcomes Research, London, London, United Kingdom

PMH14

DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
Klok RM¹, Al Hadithy AF¹, Van Schayk NP², Antonisse AJ², Brouwers JR¹, Postma MJ^1
1University of Groningen, Groningen, Groningen, Netherlands; ² AstraZeneca BV, Zoetermeer, Zuid Holland, Netherlands

PMH15

GALANTAMINE REDUCES CAREGIVER BURDEN: RESULTS FROM A NATURALISTIC STUDY
Nguyen E¹, Camacho F², Luong D^1
1Janssen-Ortho Inc, Toronto, ON, Canada; ² Damos Inc, Toronto, ON, Canada

PMH16

EFFECT OF BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) ON COST OF CARE IN THE CANADIAN OUTCOMES STUDY IN DEMENTIA
Herrmann N¹, Lanctôt K¹, Nguyen E², Sambrook R³, Lesnikova N^3
1University of Toronto and Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada; ² Janssen-Ortho Inc, Toronto, ON, Canada; ³ Syreon Corporation, Vancouver, BC, Canada

PMH17

HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS
Alvarez-Ude F¹, Valdés C², Rebollo P², Estebanez C^1
1Hospital General de Segovia. Instutute "Reina Sofía "for Nephrological Research, Segovia, Segovia, Spain; ² Hospital Universitario Central de Asturias and Institute Reina Sofia for nephrological research, Oviedo, Asturias, Spain

PMH18

TRANSLATION, GREEK ADAPTATION AND STANDARDIZATION OF THE VERONA SERVICE SATISFACTION SCALE (VSSS-54): AN INSTRUMENT PATIENTS' SATISFACTION WITH MENTAL HEALTH SERVICES
Bletsa D, Kallinikou E, Mavreas V
University of Ioannina, School of Medicine, IOANNINA, Greece

PMH19

CHANGES IN NOVEL ANTIPSYCHOTIC USE IN ELDERLY INPATIENTS
Coley KC, Gim S, Weber RJ, Ganguli R
University of Pittsburgh, Pittsburgh, PA, USA

PMH20

RELATION BETWEEN SYMPTOMS IN SCHIZOPHRENIA AND RISK OF HARM TO SELF AND OTHERS
Heeg B¹, Cahn W², Meijboom M³, Ingham M⁴, Caleo S⁵, Rabinowitz J⁶, Buskens E^3
1Pharmerit, Rotterdam, Zuid Holland, Netherlands; ² Utrecht Medical Centre, Utrecht, Utrecht, Netherlands; ³ PharMerit, Rotterdam, Netherlands; ⁴ Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA; ⁵ Janssen Pharmaceutica, Beerse, Antwerp, Belgium; ⁶ Bar Ilan University, Ramat Gan, Israel

PMH21

TREATMENT PERSISTENCE: A COMPARISON AMONG PATIENTS WITH SCHIZOPHRENIA WHO WERE INITIATED ON ATYPICAL ANTIPSYCHOTIC AGENTS
Ren XS¹, Qian S¹, Lee A², Herz L³, Miller DR¹, Kazis LE^1
1Boston University/Veterans Health Administration, bedford, MA, USA; ² Boston University, bedford, MA, USA; ³ Veterans Health Administration, bedford, MA, USA

PMH22

HOSPITALIZATION AND MEDICATION USE IN SCHIZOPHRENIA PATIENTS RECEIVING RISPERIDONE LONG-ACTING INJECTABLE OR ORAL ATYPICAL ANTIPSYCHOTIC MEDICATION
Chue P¹, Lam A², Chandra K³, Luong D², Camacho F^4
1University of Alberta, Edmonton, AB, Canada; ² Janssen-Ortho Inc, Toronto, ON, Canada; ³ McKesson Phase 4 Solutions, Toronto, ON, Canada; ⁴ Damos Inc, Toronto, ON, Canada

PMH23

IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATION AND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA
Beauclair L¹, Lam A², McCormick J³, Luong D², Camacho F^4
1McGill University, Montreal, QC, Canada; ² Janssen-Ortho Inc, Toronto, ON, Canada; ³ McKesson Phase 4 Solutions, Toronto, ON, Canada; ⁴ Damos Inc, Toronto, ON, Canada

PMH24

GEO OBSERVATIONAL STUDY: 24 MONTHS CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann F¹, Reitberger U¹, Clouth J², Czekalla J^2
1Kendle GmbH & Co GMI KG, Munchen, Germany; ² Lilly Deutschland GmbH, Bad Homburg, Germany

PMH25

EFFECTIVENESS AND TOLERABILITY OUTCOMES OF RISPERIDONE LONG-ACTING INJECTION COMPARED TO CONVENTIONAL DEPOT ANTIPSYCHOTICS IN A LARGE CANADIAN PSYCHIATRIC HOSPITAL
Snaterse MH, Welch RP
Capital Health, Edmonton, AB, Canada

PMH26

USING CLAIMS DATA TO ESTIMATE THE ANNUAL PREVALENCE OF SCHIZOPHRENIA IN THE UNITED STATES, 2002
Wu EQ, Birnbaum HG, Aggarwal J, Moulis M
Analysis Group, Boston, MA, USA

PMH27

12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
Knapp M¹, Windmeijer F², Haro JM³, Kontodimas S⁴, Brown J⁴, Tzivelekis S⁴, Novick D⁴, Ratcliffe M^4
1London School of Economics, London, United Kingdom; ² University of Bristol, Bristol, United Kingdom; ³ Sant Joan de Deu-SSM, Barcelona, Spain; ⁴ Eli Lilly and Company Ltd, Windlesham, Surrey, United Kingdom

PMH28

COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS NO TREATMENT FOR SCHIZOPHRENIA RELAPSE PREVENTION
Azanza JR¹, Bernardo M², Rubio-Terrés C³, Díez T⁴, Rejas J^5
1University Clinic of Navarra, Pamplona, Pamplona, Spain; ² Hospital Clinic i Provincial, Barcelona, Barcelona, Spain; ³ HERO Consulting, Madrid, Madrid, Spain; ⁴ Pfizer Spain, Madrid, Madrid, Spain; ⁵ Pfizer Spain, Madrid, Spain

PMH29

DRUG UTILIZATION PATTERNS AND COSTS AND TOTAL COSTS OF SCHIZOPHRENIA TREATMENT IN AN INSURED POPULATION
Wilson L, Lightwood J, Le A, Gitlin M
University of California, San Francisco, San Francisco, CA, USA

PMH30

FACTORS AFFECTING COST OF SCHIZOPHRENIA TREATMENT WITH ATYPICAL ANTIPSYCHOTIC AGENTS
Law W¹, Hui H², Young W³, You JH^4
1Kowloon Hospital, Kowloon, Kowloon, Hong Kong; ² Alice Ho Miu Ling Nethersole Hospital, Tai Po, N.T, Hong Kong; ³ The Princes of Wales Hospital, Shatin, N.T, Hong Kong; ⁴ The Chinese University of Hong Kong, Shatin, N.T, Hong Kong

PMH31

12 MONTH COST-UTILITY ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY
Knapp M¹, Windmeijer F², Haro JM³, Kontodimas S⁴, Brown J⁴, Tzivelekis S⁴, Novick D⁴, Ratcliffe M^4
1London School of Economics, London, United Kingdom; ² University of Bristol, Bristol, United Kingdom; ³ Sant Joan de Deu-SSM, Barcelona, Spain; ⁴ Eli Lilly and Company Ltd, Windlesham, Surrey, United Kingdom

PMH32

NEUROLEPTIC TREATMENT OF SCHIZOPHRENIA IN AMBULATORY CARE IN GERMANY
Gericke CA¹, Stargardt T¹, Weinbrenner S¹, Petereit F², Busse R¹, Juckel G^3
1Berlin University of Technology, Berlin, Germany; ² Techniker Krankenkasse, Hamburg, Germany; ³ Charité University Medicine, Berlin, Germany

PMH33

FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
Mullins CD, Kuznik A
University of Maryland, Baltimore, MD, USA

PMH34

LONG-TERM TREATMENT OF SCHIZOPHRENIA FOR RELAPSE PREVENTION (LASER): 6-MONTH OUTCOMES IN PATIENTS STARTED ON RISPERIDONE LONG-ACTING INJECTABLE IN GERMANY - DATA FROM THE E-STAR DATABASE
Naber D¹, Mehnert A², Rosillon D³, Farmer D⁴, Schreiner A², Jacobs A^5
1Department of Psychiatry and Psychotherapy, Hamburg, Germany; ² Janssen-Cilag GmbH, Neuss, Germany; ³ SGS Biopharma, Wavre, Belgium; ⁴ Interactive Educational Systems, Ltd, Hampton Court, Surrey, United Kingdom; ⁵ Janssen Pharmaceutica NV, Beerse, Belgium

PMH35

ARE INDIRECT COSTS MEASUREMENTS RELEVANT IN A SCHIZOPHRENIC PATIENTS POPULATION ? AN OVERVIEW OF A LONGITUDINAL STUDY IN FRANCE
Primus C¹, Dinet J¹, Martin P², Gury C^1
1sanofi-aventis France, Paris, France; ² CREST, Paris, France

PMH36

CASE STUDY OF PATTERN MIXTURE APPROACH FOR COMBINING COMPLETION RATES AND EFFICACY FOR CLINCALLY MEANINGFULL OUTCOMES IN SCHIZOPHRENIA DRUG TRIALS
Rabinowitz J
Bar Ilan University, Ramat Gan, Israel

PMH37

THE ECONOMIC BURDEN OF SCHIZOPHRENIA IN THE UNITED STATES IN 2002
Wu EQ¹, Birnbaum HG¹, Shi L², Ball DE³, Kessler RC⁴, Moulis M¹, Aggarwal J^1
1Analysis Group, Boston, MA, USA; ² Tulane University, New Orleans, LA, USA; ³ Eli Lilly and Company, Indianapolis, IN, USA; ⁴ Harvard Medical School, Boston, MA, USA

PMH38

A DISCRETE EVENT SIMULATION (DES) MODEL TO DESCRIBE SCHIZOPHRENIA
Heeg B¹, Buskens E², Ingham M³, Caleo S⁴, Rabinowitz J⁵, Van Hout B^6
1Pharmerit, Rotterdam, Zuid Holland, Netherlands; ² PharMerit, Rotterdam, Netherlands; ³ Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA; ⁴ Janssen Pharmaceutica, Beerse, Antwerp, Belgium; ⁵ Bar Ilan University, Ramat Gan, Israel; ⁶ Pharmerit BV, Rotterdam, Netherlands

PMH39

ARE QALYS SUITABLE FOR SCHIZOPHRENIA TRIALS?
Mangalore R¹, Knapp M¹, McKendrick J^2
1London School of Economics, London, United Kingdom; ² Eli Lilly and Company Ltd, Basingstoke, Hampshire, United Kingdom

PMH40

LONG-TERM MAINTENANCE OF INITIAL HEALTH RELATED QUALITY OF LIFE (HRQL) IMPROVEMENTS GAINED THROUGH ANTIPSYCHOTIC TREATMENT: 24-MONTH RESULTS FROM THE SCHIZOPHRENIA HEALTH OUTCOMES (SOHO ) STUDY.
Alonso J¹, Novick D², Belger M², Brown J², Ratcliffe M^2
1Institut Municipal d'Investigacio Medica (IMIM-IMAS), Barcelona, Spain; ² Eli Lilly and Company Ltd, Windlesham, Surrey, United Kingdom

PMH41

REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS)
Ballesteros J¹, Guemes I¹, Bobes J², Bulbena A³, Luque A⁴, Dal-Re R⁵, Ibarra N^6
1The University of the Basque Country, Leioa, Vizcaya, Spain; ² University of Oviedo, Oviedo, Oviedo, Spain; ³ Hospital del Mar, Barcelona, Barcelona, Spain; ⁴ AstraZeneca, Madrid, Madrid, Spain; ⁵ GlaxoSmithKline, Madrid, Madrid, Spain; ⁶ Maria Josefa Recio Foundation, Bilbao, Vizcaya, Spain

PMH42

COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY
Machado M¹, Davidian C², Perri D², Mahamed A², Konarski J², Poon J², Mancini D², McIntyre R², Kennedy S², Einarson T^2
1University of Chile, Santiago, Chile; ² University of Toronto, Toronto, ON, Canada

PMH43

CLINICAL COMPARISON OF SSRIS AND SNRIS IN MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS
Machado M¹, Iskedjian M², Einarson T^3
1University of Chile, Santiago, Chile; ² PharmIdeas Research & Consulting Inc, Oakville, ON, Canada; ³ University of Toronto, Toronto, ON, Canada

PMH44

DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Vis PM¹, van Baardewijk M², Einarson T^3
1Univeristy of Utrecht, Utrecht, Netherlands; ² Univeristy of Utrecht, Utrecht, Utrecht, Netherlands; ³ University of Toronto, Toronto, ON, Canada

PMH45

COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
Van Baardewijk M¹, Vis PM¹, Einarson T^2
1Univeristy of Utrecht, Utrecht, Netherlands; ² University of Toronto, Toronto, ON, Canada

PMH46

COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY
Kulp W¹, Hemels M², Greiner W³, Schulenburg Graf von der J^1
1University of Hannover, Hannover, Germany; ² H. Lundbeck A/S, Paris, France; ³ Bielefeld University, Bielefeld, Germany

PMH47

COST OF AFFECTIVE DISORDERS IN EUROPE
Andlin-Sobocki P¹, Rehnberg C², Jönsson B^3
1Stockholm Health Economics, Stockholm, Sweden; ² Karolinska Institute, Stockholm, Sweden; ³ Stockholm School of Economics, Stockholm, Sweden

PMH48

QUALITY OF LIFE IN MAJOR DEPRESSION: RESULTS OF THE MC3 TRIAL
Mantovani LG¹, Sturkenboom M^2
1Center of Pharmacoeconomics, University of Milan, Milan, Italy; ² Department of Epidemiology & Biostatistics, Rotterdam, Netherlands

PMH49

QUALITY OF LIFE IN MAJOR DEPRESSION: RESULTS OF THE MC4 TRIAL
Mantovani LG¹, Sturkenboom M^2
1Center of Pharmacoeconomics, University of Milan, Milan, Italy; ² Department of Epidemiology & Biostatistics, Rotterdam, Netherlands

PMH50

DEVELOPMENT OF A COMPREHENSIVE EMOTIONAL, SOMATIC AND PAINFUL PHYSICAL SYMPTOMS CHECKLIST IN DEPRESSION IN FIVE EUROPEAN COUNTRIES
Arnould B¹, Garcia-Cebrian A², Dard S³, Monz B⁴, Brown J², Hugonot-Diener L^5
1Mapi Values, Lyon, Rhone, France; ² Eli Lilly, Windlesham, England; ³ Mapi Values, Lyon, France; ⁴ Boehringer Ingelheim, Ingelheim, Germany; ⁵ Medforma, Paris, France

.........................TOP

PRS1

CLINICAL AND TREATMENT FACTORS INFLUENCING THE OUTCOME OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS: LESSONS FOR FURTHER CLINICAL AND OUTCOMES RESEARCH
Sagnier PP¹, Wilson R², Jones P³, Schaberg T⁴, Arvis P⁵, Moyse D^6
1Bayer Health Care Pharma, Uxbridge, England, United Kingdom; ² Royal Brompton Hospital, London, United Kingdom; ³ St George's Hospital Medical School, London, United Kingdom; ⁴ Diakoniekrankenhaus, Rotenburg, Germany; ⁵ Bayer Health Care Pharma, Puteaux, France; ⁶ D Moyse Consultant, Paris, France

PRS2

PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION
Gothe H¹, Sandtmann R², Hoeer A¹, Schiffhorst G¹, Storz P¹, Glaeske G³, Haeussler B^1
1IGES, Berlin, Germany; ² ALTANA Pharma AG, Konstanz, Germany; ³ University of Bremen, Bremen, Germany

PRS3

COST ANALYSIS OF FOUR TREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE: AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP
Fattore G¹, Torbica A¹, Mangone M^2
1Bocconi University, Milano, Mi, Italy; ² AstraZeneca S.p.a, Basiglio, Milan, Italy

PRS4

INHALED CORTICOSTEROIDS AND BROCHODILATORS FOR SEVERE AND VERY SEVERE COPD PATIENTS: COST-EFFECTIVENESS AND HEALTH CARE BUDGET IMPACT IN ITALY
Pradelli L¹, Iannazzo S¹, Dal Negro RW², Eandi M^3
1Advanced Research Srl, Torino, Italy; ² ASL 22, Bussolengo (VR), Italy; ³ University of Turin, Torino, Italy

PRS5

PHARMACOECONOMIC EVALUATION OF TIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
De Lucas P¹, Rodríguez JM², Gobartt E³, Soto J⁴, Martin A^4
1Gregorio Marañon Hospital, Madrid, Spain; ² Gregorio Marañon Hospital, Madrid, Madrid, Spain; ³ Boehringer Ingelheim Spain, Sant Cugat del Valles, Barcelona, Spain; ⁴ Pfizer Spain, Alcobendas, Madrid, Spain

PRS6

ECONOMIC EVALUATION OF TIOTROPIUM AND SALMETEROL IN THE TREATMENT OF COPD IN GREECE
Maniadakis N¹, Tzanakis N¹, Geitona M², Fragoulakis V³, Hatzikou M⁴, Siafakas N^1
1University Hospital of Heraklion, Crete, Greece; ² University of Thessaly, Dionisos, Greece; ³ Foundation for Economic and Industrial Research, Athens, Greece; ⁴ Boehringer Ingelheim Hellas, Elliniko, Greece

PRS7

COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND
Pirozynski M¹, Bartminski W², Czech M², Faluta T², Pachocki R^2
1Medical Center for Postgraduate Education, Warsaw, Poland; ² Servier Poland, Warsaw, Poland

PRS8

COST-EFFECTIVENESS OF FLUTICASONE PROPIONATE NASAL DROPS VERSUS SURGICAL TREATMENT FOR NASAL POLYPOSIS IN POLAND
Golicki D¹, Latek M², Niewada M¹, Glogowski C³, Kukwa W¹, Macioch T^1
1Medical University of Warsaw, Warsaw, Poland; ² Warsaw School of Economics, Warsaw, Poland; ³ GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland

PRS9

COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND.
Kawalec P¹, Lis J², Gierczynski J^2
1Jagiellonian University, Krakow, Poland; ² Sanofi-aventis Poland, Warsaw, Poland

PRS10

PROJECTING THE FUTURE COSTS OF ASTHMA AND COPD IN THE NETHERLANDS
Hoogendoorn M¹, Rutten-van Molken MP¹, Feenstra TL^2
1Erasmus MC, Rotterdam, Netherlands; ² National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands

PRS11

MANAGEMENT OF COPD IN BELGIUM : A REAL LIFE COST OF ILLNESS STUDY
Caekelbergh K, Spaepen E, Annemans L
IMS Health, Brussels, Belgium

PRS12

THE BURDEN OF LUNG DISEASE (BOLD) ECONOMIC MODEL
Sullivan S¹, Lee T², Weiss K², Buist S³, Vollmer W^4
1University of Washington, Seattle, WA, USA; ² Northwestern University, Chicago, IL, USA; ³ Oregon Health and Sciences Center, Portland, OR, USA; ⁴ Kaiser Permanente, Portland, OR, USA

PRS13

COST ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION DURING TREATMENT FOR RESPIRATORY TRACK INFECTIONS (RTIS) WITH TELITHROMYCIN OR CLARITHROMYCIN OR AMOXICILLIN/CLAVULANIC ACID IN GREECE
Angeli A¹, Maniadakis N^2
1Sanofi Aventis Greece, Athens, Athens, Greece; ² University Hospital of Heraklion, Crete, Greece

PRS14

HEALTHCARE RESOURCES UTILIZATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACCORDING TO THEIR SEVERITY IN SPAIN
De Lucas P¹, Rodríguez JM¹, Martin A², Soto J^2
1Gregorio Marañon Hospital, Madrid, Spain; ² Pfizer Spain, Alcobendas, Madrid, Spain

PRS15

OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA
Eichmann F¹, Reitberger U¹, Caeser M^2
1Kendle GmbH & Co GMI KG, München, Germany; ² Altana Pharma AG, Konstanz, Germany

PRS16

CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A COMPARISON OF ESTIMATES OF HEALTH-RELATED UTILITY (EQ5D) FROM SF36 DATA ALONE, THE SF36 PLUS LUNG FUNCTION DATA, AND THE SF36 PLUS THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE PLUS LUNG FUNCTION DATA
Savani V¹, Currie CJ¹, Griffin J², Loftus J³, McEwan P^1
1Cardiff University, Cardiff, Wales, United Kingdom; ² Boehringer Ingelheim Limited, Bracknell, Berkshire, United Kingdom; ³ Pfizer, Tadworth, Surrey, United Kingdom

PRS17

QUALITY OF LIFE IN COPD: HOW CAN WE MEASURE IT?
Leiva F¹, Garcia A², Prados D¹, Martos F³, Sanchez de la Cuesta F^3
1Servicio Andaluz de Salud, Málaga, Spain, Spain; ² Universidad de Málaga, Málaga, Spain; ³ Universidad de Málaga, Málaga, Málaga, Spain

PRS18

DOES QUALITY OF LIFE OF COPD PATIENTS AS MEASURED BY THE GENERIC EQ-5D DIFFERENTIATE BETWEEN COPD SEVERITY STAGES?
Rutten-van Molken MP¹, Oostenbrink JB¹, Monz BU^2
1Erasmus MC, Rotterdam, Netherlands; ² Boehringer Ingelheim International, Ingelheim, Germany

PRS19

IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS – DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS
Arnould B¹, Prost L¹, Pérez T², Roche N³, Aguilaniu B⁴, N'Guyen JM^5
1Mapi Values, Lyon, Rhone, France; ² Calmette Hospital, Lille, France; ³ Hôtel Dieu Hospital, Paris, France; ⁴ Hylab, Grenoble, France; ⁵ Altana Pharma, Le Mée sur Seine, France

PRS20

PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS – SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q
Mesrobian X¹, Crawford B², Tetzlaff K³, Monz B^4
1Mapi Values USA, Boston, MA, USA; ² Mapi Values, Boston, MD, USA; ³ Boehringer Ingelheim, Biberach/Riss, Germany; ⁴ Boehringer Ingelheim, Ingelheim, Germany

PRS21

PATIENT SATISFACTION WITH TREATMENT FOR COPD
Leiva F¹, Garcia A², Prados D¹, Sanchez de la Cuesta F³, Martos F^3
1Servicio Andaluz de Salud, Málaga, Spain, Spain; ² Universidad de Málaga, Málaga, Spain; ³ Universidad de Málaga, Málaga, Málaga, Spain

.........................TOP

PSU1

THE SOCIETAL COST OF AUTOLOGOUS, ALLOGENEIC AND PERIOPERATIVE RBC TRANSFUSION – THE CASE OF SWEDEN
Persson U¹, Glenngård AH¹, Söderman C², Lycke J^2
1IHE, The Swedish Institute for Health Economics, Lund, Sweden; ² Janssen-Cilag, Sollentuna, Sweden

PSU2

COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO
Carlos FDJ, Guzmán JA, Camacho A
RAC Salud Consultores, S.A. DE C.V, Ciudad de México, Distrito Federal, Mexico

PSU3

THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY
Borin F¹, Maselli MA², Scalone L³, Pezzolla F², Demma I², Amboldi A¹, Mantovani LG^3
1Presidio Ospedaliero di Rho, Azienda Ospedaliera G. Salvini, Rho (Milan), Italy; ² IRCCS S. de Bellis Hospital, Castellana Grotte (Bari), Italy; ³ Center of Pharmacoeconomics, Milan, Italy

PSU4

TOTAL INSURANCE COST OF TREATMENT OF HIP FRACTURES ACCORDING TO THE LOAD STABILITY OF DIFFERENT SURGICAL METHODS
Sebestyen A¹, Boncz I², David T², Toth F³, Nyarady J^3
1National Health Insurance Fund Administration (OEP), Pécs, Hungary; ² National Health Insurance Fund Administration (OEP), Budapest, Hungary; ³ University of Pécs, Pécs, Hungary

PSU5

FACTORS ASSOCIATED WITH BLOOD TRANSFUSION COSTS DURING AND FOLLOWING SPINAL SURGERY IN THE UNITED STATES
Wang PF¹, Joshi AV², Kruse P², Asmussen M³, Saunders B^1
1Premier Inc, Charlotte, NC, USA; ² Novo Nordisk Inc, Princeton, NJ, USA; ³ Novo Nordisk A/S, Bagsvaerd, Denmark

PSU6

DIFFERENCES IN BLOOD TRANSFUSION COSTS BY HIP AND KNEE REPLACEMENT AND REVISION SURGERY SUBTYPES
Joshi AV¹, Wang PF², Kruse P¹, Asmussen M³, Saunders B^2
1Novo Nordisk Inc, Princeton, NJ, USA; ² Premier Inc, Charlotte, NC, USA; ³ Novo Nordisk A/S, Bagsvaerd, Denmark

PSU7

"TECHNO-MARKERS" FOR THE ASSESSMENT OF HEALTH TECHNOLOGY UTILIZATION
Ostfeld I¹, Abadi-Korek I¹, Tamir O¹, Harar G², Vidne B³, Shemer J^1
1The Gertner Institute for Epidemiology and Health Policy Research, Ramat Gan, Non, Israel; ² The Gertner Institute for Epidemiology & Health Policy research, Ramat Gan, Israel; ³ Rabin Medical Center, Petah Tikva, Israel

PSU8

APPLICATION OF (PRO)SPECTIVE STUDY OF PATIENT SATISFACTION (PS) TO MONITOR QUALITY AND TO SUPPORT MANAGEMENT OF HEALTH CARE PROVIDER – AN EXAMPLE OF MEETING ISO 9001:2000 REQUIREMENTS BY THE CARDIOSURGICAL UNIT IN POLAND.
Koltowski LN¹, Kosela J^2
1Leon Kozminski Academy of Enterpreneurship and Management, Warsaw, Poland; ² University of Greenwich, London, United Kingdom

.........................TOP